Need Help?
No Article Versions Notes Found
Cite
Hirsh, V.; Melosky, B.; Goss, G.; Morris, D.; Morzycki, W. A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada. Curr. Oncol. 2012, 19, 78-90. https://doi.org/10.3747/co.19.1018
Hirsh V, Melosky B, Goss G, Morris D, Morzycki W. A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada. Current Oncology. 2012; 19(2):78-90. https://doi.org/10.3747/co.19.1018
Chicago/Turabian StyleHirsh, V., B. Melosky, G. Goss, D. Morris, and W. Morzycki. 2012. "A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada" Current Oncology 19, no. 2: 78-90. https://doi.org/10.3747/co.19.1018
APA StyleHirsh, V., Melosky, B., Goss, G., Morris, D., & Morzycki, W. (2012). A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada. Current Oncology, 19(2), 78-90. https://doi.org/10.3747/co.19.1018
